Join our daily newsletter At The Bell to receive exclusive market insights
- EMVision Medical Devices (EMV) partners with Keysight Technologies Australia to continue developing a new generation of portable brain scanners
- The 12-month deal grants EMVision exclusivity to supply Keysight’s “fast sweep” feature in the Vector Network Analysers (VNA) solution, which both companies worked to develop
- The feature in the VNA enables high fidelity imaging, allowing EMVision’s portable brain scanner to be further miniaturised for environments like ICUs
- EMV shares have been up 8.25 per cent, trading at $2.10
EMVision Medical Devices (EMV) has entered an original equipment manufacturer agreement with Keysight Technologies Australia.
Under the initial 12-month deal, EMVision will hold exclusivity for the supply of Keysight’s “fast sweep” feature in the Vector Network Analysers (VNA), which is core to the sensors used inside EMV’s portable brain scanner.
The companies previously collaborated in early 2019 to develop the healthcare-focused VNA solutions that are the subject of this agreement.
The VNA solution is a high performance, lower component count, miniaturised module responsible for accurate signal measurement. The “fast sweep” feature in the VNA enables high fidelity imaging, and due to the speed of data capture, the measurement of cerebral blood flow through EMVision’s “pulsatility” technique under development.
Additionally, the VNA allowed the EMVision device to be further miniaturised which makes it ideal for environments like ICUs and, in the future, ambulances. The integrated VNA also eliminates the need for expensive cabling, and lowers the component count which optimises product margins.
Senior Vice President of Keysight Technologies, Huei Sin Ee said she was looking forward to expanding the partnership with EMVision.
“Combining Keysight’s test and measurement expertise and best-in-class solutions with EMVision’s clinical product development expertise is anticipated to revolutionize emergency stroke diagnosis and treatment.”
EMVision CEO, Dr Ron Weinberger said the collaboration with Keysight has been “first class.”
“This agreement recognises the roles that both parties have played in the development of the bespoke VNA over a period of three years. I would like to thank the Keysight team for their concerted work in developing a best-of-breed solution for EMVision and look forward to the commercial phase of our relationship,” Dr Weinberger said.
EMVision hasn’t disclosed the financial impact of the 12-month agreement but said it isn’t considered material.
EMV was up 8.25 per cent with shares trading at $2.10 at 11:30 am AEST.
